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Cell and gene therapies (CGTs) are progressively entering into clinical practice in different parts of the world. The Interna-
tional Society for Cell & Gene Therapy (ISCT), a global scientific society, has been committed since 1992 to supporting and
developing knowledge on clinical applications of CGTs. Considering the number of products that have been progressively
approved and, in some cases, withdrawn in recent years, the ISCT would like to present a brief annual report on CGTs with
marketing authorization (MA) in different regions. This article reflects the dynamic momentum around authorized CGTs
coinciding with the parallel increase of unproven approaches where cells are delivered without appropriate and rigorous sci-
entific and regulatory assessment and authorization. This is intended to be a living document with a yearly update linked to a
dedicated section of the ISCT website for faster adjustments. The aim is to ultimately inform, by periodic snapshots, the sci-
entific community, healthcare stakeholders and patient associations on authorized CGT products as a way to increase com-
munication around the approved therapeutic approaches charged with heightened expectations.Introduction
The International Society for Cell & Gene Therapy
(ISCT) is committed to translating cellular therapy
into safe and effective treatments to improve
patients’ lives while minimizing and balancing risks
for patients. Being aware that many unproven or
insufficiently proven cell-based treatments are
commercially available for hopeful individuals
seeking cures or health improvement for a variety
of conditions, the ISCT created the ISCT Presi-
dential Task Force (PTF) on the Use of Unproven
Cellular Therapies (UCT) in 2014. The PTF-
UCT strives to characterize unproven cellular
interventions and promote safe and effective prac-
tices worldwide [1,2].
In line with the above goals, the PTF-UCT has
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In this document the PTF-UCT has summarized
cell, tissue and gene medicinal products authorized
for commercialization by regions/countries, to help
patients seeking safe and effective treatments. We
have not included any products that are categorized
as medical devices, even if they are cell-based. If
a patient lives in one of the regions/countries
included in the document and a healthcare profes-
sional or a business is offering a cell-based treat-
ment not listed, they should ask whether they are
going to receive the treatment as part of a clinical
trial. If not, the ISCT recommends asking for more
information about the “regulatory status” of the
treatment they are going to receive to make an
informed decision.Advanced Therapies/Iniciativa Andaluza en Terapias Avanzadas, Junta de
nce: Laertis Ikonomou, PhD, Center for Regenerative Medicine of Boston
2118, USA. E-mail: natividad.cuende.sspa@juntadeandalucia.es,
blished by Elsevier Inc. This is an open access article under the CC BY-NC-
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Human cell or tissue-based products are highly het-
erogeneous and regulatory authorities will always
apply their rulings on a case-by-case basis. Neverthe-
less, at present, most of the cell- and tissue-based
products are considered biological medicinal products
in those countries with more developed regulatory
structures. The development of safe and effective
“proven” cell therapies requires testing these medici-
nal products according to some general principles [3].
Before administration into humans, both biological
activity and toxicity of the investigational medicinal
product must be tested in relevant animal model(s).
Researchers must then seek approval of an institu-
tional review board (IRB) for all centers involved in
the clinical trial as well as an authorization from the
national regulatory agencies of the countries where
patients will be recruited, irrespective of their nation-
alities. The sponsor’s duties also include ensuring: (i)
that there is an insurance policy in place to cover any
liability, (ii) that recruitment of subjects is done after
appropriate informed consent and (iii) that medicinal
product batches for release conform to specifications.
If the regulatory bodies determine that quality, safety
and efficacy of a cell- or tissue-based medicinal prod-
uct are sufficiently established through successful clin-
ical phases (clinical trial phase 1, 2 and 3), then the
next step is to apply for marketing authorization
(MA). After that, the company that holds the MA can
commercialize the medicinal product in the countries
in which the product has been granted MA. In some
cases, MA is provisional and post-marketing surveil-
lance studies are required. Of note, some countries
permit exceptions to this authorization rule depending
on the nature of the medicinal product, be it industrial
or otherwise. In any case, the use of a medicinal prod-
uct has to be supervised by a regulatory body.Identified cell and gene therapies with MA
We have identified and listed cell and gene therapies
(CGTs) with MA based on available information,Table I. List of cell/tissue/gene products with MA in Australia by TGA.
Name (MA holder) Product description and
indication(s)
Product cate
Chondrocytes - T -
Ortho-ACI (Orthocell
Pty Ltd)
Autologous cultured
chondrocytes for use
in treatment of carti-
lage lesions associated
with the knee, patella
and ankle
Cell therapy
TGA, Therapeutic Goods Administration.considering as a source of trustworthy information
the regulatory body web resources, official press
release by the interested companies or other source
of data as indicated in Tables IX where countries/
regions are listed in alphabetical order. The list has
been updated as of September 15, 2018, unless oth-
erwise specified.
In Figure 1, we present the distribution of
authorized CGT products by region. In addition,
we have listed (Table XI) the CGT approaches
that have received a Regenerative Medicine
Advanced Therapy (RMAT) designation by the
United States Food and Drug Administration
(USFDA) [4] but have not been approved as of
September 2018. In Figure 2, we have categorized
CGT products with MA worldwide in three
different ways, namely, by product, therapy and
disease type. Finally, in Figure 3 we present CGT
products according to the year in which they
received MA.
Several products are currently available in dif-
ferent regions but have the same MA holder
(YESCARTA, KYMRIAH, IMLYGIC, RMS Oss-
ron/OSSGROW and Chondron/CARTIGROW).
These products are taken into account only once in
Figures 2 and 3, leading to a total number of 44
unique products.Discussion and conclusions
The goal of this article is to provide a quick reference
for anyone interested in a snapshot, to be updated
annually, of the CGT landscape worldwide. This list
may not be exhaustive and additional CGT products
with MA will be included in future updates. To our
knowledge, no cell/tissue/gene products have been
authorized for marketing in Brazil, Hong Kong,
Israel, Malaysia, Singapore and Taiwan as of Sep-
tember 2018.
We have identified 44 unique products, 37 of
them are cell and tissue therapies (84%) and mainly
autologous (55%) (Figure 2). As far as targeted dis-
eases are concerned, more than one third of thegory Date of MA Current status Additional
information
product 26-Mar-2017 Still in market Click here for
link to TGA
website
Table III. List of cell/tissue/gene products with MA in China by CSFDA.
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
Gendicine (Shenzhen SiBiono
GeneTech Co. Ltd.)
Recombinant adenovirus
expressing p53 for treat-
ment of head and neck
squamous cell carcinoma
Gene therapy product Oct-2003 Still in market Click here
CSFDA, Chinese Food and Drug Administation.
Table II. List of cell/tissue/gene products with MA in Canada by Health Canada (March 2018).
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
KYMRIAH (NOVARTIS
PHARMACEUTI-
CALS CANADA INC)
CD19-directed genetically
modified autologous T-cell
immunotherapy indicated for
the treatment of pediatric
and young adult patients
325 y with B-cell ALL who
are refractory, have relapsed
after allogeneic SCT or are
otherwise ineligible for SCT,
or have experienced second
or later relapse and for the
treatment of adult patients
with relapsed or refractory
large B-cell lymphoma after
two or more lines of systemic
therapy including DLBCL
not otherwise specified, high-
grade B-cell lymphoma and
DLBCL arising from follicu-
lar lymphoma.
Gene therapy
product
05-Sep-2018 In market Click here for
link to Health
Canada
website
Prochymal (MESO-
BLAST INTERNA-
TIONAL SARL)
Allogeneic ex vivocultured
adult human mesenchymal
stromal cells for the manage-
ment of aGvHD in pediatric
patients
Cell therapy
product
02-May-2015 The product was
never marketed
in Canada
Click here for
link to Health
Canada
website
ALL, acute lymphoblastic leukemia; SCT, stem cell transplantation; DLBCL, diffuse large B-cell lymphoma; aGVHD, acute graft-versus-
host disease.
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cal or hematologic diseases.
As shown in Figure 3, the number of products with
MA has increased in recent years. For example, those
authorized from 2015 to September 2018 represent
45%. Unfortunately, there has been a parallel increase
in the number of businesses offering unproven and
unlicensed cell-based interventions [5,6].
Even though the distribution of authorized CGTs
shows important differences among countries or
regions, it is not our intention to debate the complex
financial, societal and scientific reasons behind these
differences or the impact of different regulatorysystems on the number of marketed products. As
members of the ISCT PTF-UCT, our main objec-
tive is to help patients make informed decisions
before receiving a cell or gene treatment so that they
can avoid being exposed to unproven and unlicensed
cell interventions. For that purpose, we aim to pro-
vide a reliable, up-to-date resource where patients or
professionals can check whether a cell or gene ther-
apy has been approved by a regulatory/medicine
agency.
As mentioned before, the ISCT recommends
asking for information about the “regulatory status”
of the treatment patients are going to receive to make
Table IV. List of Cell/Tissue/Gene Products with MA in Europe by EMA.
Name (MA holder) Product description and
indication(s)
ATMP Date of MA Current status Additional
information
YESCARTA (Kite
Pharma EUB.V.)
CD19-directed genetically modi-
fied autologous T cell immuno-
therapy indicated for the
treatment of adult patients with
relapsed or refractory DLBCL
and PMBCL, after two or more
lines of systemic therapy
GTMP 23-Aug-2018 Details of MA condi-
tions not displayed at
EMA website as of
31-Aug-2018
Click here for
link to EMA
website
KYMRIAH (Novartis
Europharm
Limited)
CD19-directed genetically modi-
fied autologous T-cell immuno-
therapy indicated for the
treatment of pediatric and young
adult patients up to 25 y of age
with B-cell ALL that is refrac-
tory, in relapse post-transplanta-
tion or in second or later relapse,
and for the treatment of adult
patients with relapsed or refrac-
tory DLBCL after two or more
lines of systemic therapy
GTMP 27-Aug-2018 Details of MA condi-
tions not displayed at
EMA website as of
31-Aug-2018
Click here for
link to EMA
website
ALOFISEL (Takeda
Pharma A/S)
Expanded allogeneic adipose stem
cells as a suspension for injection
for the treatment of complex
perianal fistulas in patients with
Crohn’s disease
SCTMP 27-Mar-2018 The company will com-
plete a study to con-
tinue to collect
information on the
effectiveness and
safety
Click here for
link to EMA
website
SPHEROX (CO.
DONAG)
Spheroids of human autologous
matrix-associated chondrocytes
for knee-repairing cartilage
defects
TEP 10-Jul-2017 MA under several obli-
gations (post-authori-
zation long-term
efficacy and safety
study, prospective pro-
cess validation study
and re-validation of
the potency assay)
Click here for
link to EMA
website
ZALMOXIS
(MolMed SpA)
Donor’s T lymphocytes genetically
modified with a suicide gene as a
control mechanism for GVHD
after haploidentical bone mar-
row transplantation
GTMP 18-Aug-2016 Granted MA under
conditional approval
Click here for
link to EMA
website
STRIMVELIS (GSK
Trading Services
Limited)
Autologous CD34+ cells trans-
duced with a retroviral vector
that encodes for the human
ADA cDNA sequence for severe
combined immunodeficiency
due to ADA deficiency
GTMP 26-May-2016 Granted MA under
additional monitoring
until 2037
Click here for
link to EMA
website
IMLYGIC (Amgen
Europe B.V.)
Oncolytic immunotherapy derived
from a herpex simplex virus-1
genetically engineered to infect
and replicate within melanoma
cells and to produce GM-CSF
for unresectable melanoma
GTMP 16-Dec-2015 Granted MA under
additional monitoring
Click here for
link to EMA
website
HOLOCLAR (Chiesi
Farmaceutici S.p.A.)
Ex vivoexpanded autologous
human corneal epithelial cells
containing stem cells for severe
limbal stem cell deficiency
SCTMP 17-Feb-2015 Granted MA under
conditional approval
Click here for
link to EMA
website
EMA, European Medicines Agency; ATMP, Advanced Therapy Medicinal Product; PMBCL, primary mediastinal large B-cell lymphoma;
ADA, Adenosine deaminase; cDNA, complementary DNA; TEP, Tissue Engineered Product; GTMP, Gene Therapy Medicinal Product;
SCTMP, Somatic Cell Therapy Medicinal Product; EC, European Commission.
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Table V. List of cell/tissue/gene products with MA withdrawn or suspended in Europe by EMA.
Name (MA holder) Product description and
indication(s)
ATMP Date of MA Current status Additional
information
PROVENGE
(Dendreon)
Autologous peripheral-blood
mononuclear cells activated
with prostatic acid phospha-
tase granulocyte-macrophage
colony-stimulating factor for
metastatic prostate cancer
SCTMP 6-Sep-2013 Granted MA under
additional monitoring.
Withdrawn: company
announced bank-
ruptcy in 2015
Click here for
link to EMA
website
MACI (Aastrom
Biosciences, Inc.)
Matrix applied characterized
autologous cultured chon-
drocytes for repairing knee
cartilage defects
TEP 27-Jun-2013 Granted MA under
additional monitoring.
MA suspended: 25-
Sep-2014
Click here for
link to EMA
website
GLYBERA (uniQure
biopharma BV)
Alipogene tiparvovec (human
lipoprotein lipase gene vari-
ant in a adeno-associated
viral vector) for adult patients
with familiar lipoprotein
lipase deficiency
GTMP 25-Oct-2012 Granted MA under
additional monitoring.
Withdrawn: MA
expired on 25-Oct-
2017. The company
did not apply for
renewal due to the
lack of demand
Click here for
link to EMA
website
CHONDROCELECT
(TiGenix NV)
Characterized viable autolo-
gous cartilage cells expanded
ex vivo for repairing knee car-
tilage defects
TEP 5-Oct-2009 The product was reim-
bursed in 3 countries.
Withdrawn: 30-Nov-
2016. Requested by
the company for com-
mercial reasons
Click here for
link to EMA
website
Table VI. List of cell/tissue/gene products with MA in India by DCGI.
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
CARTIGROWTM
(Chondron ACI)
(RMS Regrow)
Autologous cultured carti-
lage cells for treatment of
articular cartilage defects
Cell therapy
product
Apr-2017 Conditional approval, post-
market surveillance study
required (50 subjects)
Click here
OSSGROWTM
(Ossron ABI) (RMS
Regrow)
Autologous cultured osteo-
blasts for avascular necro-
sis of hip
Cell therapy
product
Apr-2017 Conditional approval, post-
market surveillance study
required (50 subjects)
APCEDEN (APAC
Biotech)
Autologous monocyte-
derived mature dendritic
cells for treatment of
prostate, ovarian, colorec-
tal and non-small cell
lung carcinoma
Cell therapy
product
Mar-2017 Conditional approval, post-
market surveillance study
required
Click here
Stempeucel (Stem-
peutics Research)
Ex vivocultured adult
allogeneic mesenchymal
stromal cells for treat-
ment of critical limb
ischemia due to Throm-
boangiitis Obliterans
(Buerger’s disease)
Cell therapy
product
May-2016 In market, limited release (200
patients on a cost recovery
basis), post-market surveil-
lance study required
Click here
DCGI, Drug Controller General of India.
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patients living in one of the regions/countries
included in the document who seek safe and effective
treatments, should a healthcare professional or a
business offer a CGT that is neither listed nor part of
a clinical trial.Acknowledgments
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Table VII. List of cell/tissue/gene products with MA in Japan by PMDA.
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional information
(In Japanese)
Temcell HS (JCR
Pharmaceuticals
Co. Ltd.)
Allogeneic mesenchymal
stromal cells for treat-
ment of aGVHD
Cell therapy
product
Sep-2015 In market Click here for link to
PMDA website
HeartSheet (Terumo
Corporation, Ltd.)
Autologous skeletal myoblast
sheet product for the treat-
ment of severe heart failure
Tissue engi-
neered product
Sep-2015 Conditional
approval
Click here for link to
PMDA website
JACC (J-TEC) Autologous cultured
cartilage
Tissue engi-
neered product
Jul-2012 Still in market,
previous autho-
rization was as
medical device
Click here for link to
PMDA website
JACE (J-TEC) Autologous cultured epi-
dermis for treatment of
severe burns
Tissue engi-
neered product
Oct-2007 Still in market,
previous autho-
rization was as
medical device
Click here for link to
PMDA website
PMDA, Pharmaceuticals and Medical Devices Agency.
Table VIII. List of cell/tissue/gene products with MA in New Zealand by MEDSAFE.
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
Prochymal (Osiris Ther-
apeutics Incorporated)
Allogeneic ex vivocultured
adult human mesenchymal
stromal cells indicated for the
rescue of patients NLT 6 mo
to 17 y of age with aGVHD,
refractory to treatment with
systemic corticosteroid ther-
apy or other immunosup-
pressive agents
Cell therapy
product
14-Jun-2012 Approval lapsed Click here for
link to MED-
SAFE website
MEDSAFE, Medicines and Medical Devices Safety Authority; NLT, Not Lower Than.
Table IX. List of cell/tissue/gene products with MA in South Korea by MFDS.
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
KeraHeal-AlloTM
(Biosolution
Co., Ltd.)
Composite cell product (allo-
geneic skin-derived keratino-
cytes suspended in a
thermosensitive hydrogel) for
deep 2nd degree burns
Cell therapy
product
16-Oct-2015 Still in market Click here for
link to MFDS
website
NEURONATA-R
(Corestem, Inc.)
Autologous bone marrow mes-
enchymal stromal cell ther-
apy for Amyotrophic Lateral
Sclerosis
Cell therapy
product
30-Jul-2014 Orphan product Click here for
link to MFDS
website
Cupistem
(Anterogen)
Autologous adipose
tissuederivedmesenchymal
stromal cell for Crohn’s fistula
Cell therapy
product
18-Jan-2012 Covered by
insurance as of
Jan-2014,
orphan
product
Click here for
link to MFDS
website
CARTISTEM
(Medipost Co.,
Ltd.)
Human umbilical cord blood-
derived mesenchymal stro-
mal cells for the treatment of
knee articular cartilage
defects in patients with oste-
oarthritis (ICRS grade IV)
Cell therapy
product
18-Jan-2012 Still in market Click here for
link to MFDS
website
(continued)
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Table IX. (Continued).
Name (MA holder) Product description and
indication(s)
Product category Date of MA Current status Additional
information
Cellgram-AMI
(Pharmicell Co.,
Ltd.)
Autologous bone
barrowderived mesenchymal
stromal cells for acute myocar-
dial infarction patients
(improvement of LVEF)
Cell therapy
product
1-Jul-2011 Name at time of
approval was
Heart-
icellgram-
AMI,
still in market
Click here for
link to MFDS
website
CureSkin Inj. (S.
Biomedics Co.,
Ltd.)
Autologous dermal fibroblasts
(depressed acne scar)
Cell therapy
product
11-May-2010 Still in market Click here for
link to MFDS
website
Queencell
(Anterogen)
Autologous adipose tis-
suederived adipose cell by
minimal manipulation for
subcutaneous tissue defect
Cell therapy
product
26-Mar-2010 Still in market Click here for
link to MFDS
website
Kaloderm (Tego
Science, Inc)
Allogeneic keratinocytes (cell
sheet) for deep 2nd degree
burn or diabetic foot ulcer
Tissue engi-
neered product
21-Mar-2005 (2nd
degree burn) 24-Jun-
2010 (Diabetic foot
ulcer)
Still in market Click here for
link to MFDS
website
RMSOssronTM
(Sewon Cellon-
tech Co., Ltd.)
Cultured autologous osteo-
blasts for focal bone forma-
tion, can be used with or
without fibrin glue
Cell therapy
product
26-Aug-2009 Still in market Click here for
link to MFDS
website
Immuncell-LC
(GC Cell Corp.)
Autologous activated T cell for
liver cancer (hepatocellular
carcinoma)
Cell therapy
product
6-Aug-2007 Currently in
market for
hepatocellular
carcinoma and
in clinical trials
for newly diag-
nosed glioblas-
toma (phase 3,
completed)
advanced pan-
creatic cancer
(phase 2,
completed)
Click here for
link to MFDS
website
CreaVax-RCC
(JW CreaGene
Corporation)
Autologous dendritic cells for
metastatic renal cell
carcinoma
Cell therapy
product
15-May-2007 Received tenta-
tive approval in
2007 and prod-
uct manufac-
ture license as
export product
in 2013 from
MFDS
Click here for
link to MFDS
website
KeraHeal (Bio-
solution Co.,
Ltd.)
Autologous skin-derived kera-
tinocytes for deep 2nd degree
burns that cover >30% of
TBSA and 3rd degree burns
that cover >10% of TBSA
Cell therapy
product
3-May-2006 Still in market Click here for
link to MFDS
website
Holoderm (Tego
Science, Inc)
Autologous keratinocytes for
deep 2nd degree burns that
cover >30% of TBSA and
3rd degree burns that cover
>10% of TBSA
Tissue engi-
neered product
10-Dec-2002 Still in market,
reimbursed by
insurance
Click here for
link to MFDS
website
ChondronTM
(Sewon Cellon-
tech Co., Ltd.)
Cultured autologous chondro-
cytes for focal cartilage defect
of knee, can be used with or
without fibrin glue
Cell therapy
product
30-Jan-2001 Still in market Click here for
link to MFDS
website
MFDS, Ministry of Food and Drug Safety; ICRS, International Cartilage Regeneration & Joint Preservation Society; LVEF, left ventricular
ejection fraction; TBSA, Total Burn Surface Area.
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Table X. List of cell/tissue/gene products with MA in the United States by USFDA.
Name (MA holder) Product description and indication(s) Product category Date of MA Current status Additional
information
HPC, Cord Blood
(MDAnderson
Cord Blood Bank)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
06-Jun-2018 Still in market Click here for
link to FDA
website
LUXTURNA (voreti-
gene neparvovec-
rzyl) (Spark Thera-
peutics, Inc.)
Adeno-associated virus vector-based gene
therapy indicated for the treatment of
patients with confirmed biallelic RPE65
mutation-associated retinal dystrophy
Gene therapy
product
19-Dec-2017 Still in market Click here for
link to FDA
website
YESCARTA (axicab-
tagene ciloleucel)
(Kite Pharma,
Incorporated)
A CD19-directed genetically modified
autologous T-cell immunotherapy indi-
cated for the treatment of adult patients
with relapsed or refractory large B-cell
lymphoma after two or more lines of
systemic therapy, including DLBCL
not otherwise specified, primary medi-
astinal large B-cell lymphoma, high-
grade B-cell lymphoma and DLBCL
arising from follicular lymphoma
Gene therapy
product
18-Oct-2017 Still in market Click here for
link to FDA
website
KYMRIAH (tisagen-
lecleucel) (Novartis
Pharmaceuticals
Corporation)
CD19-directed genetically modified
autologous T-cell immunotherapy indi-
cated for the treatment of patients up to
25 y of age with B-cell precursor ALL
that is refractory or in second or later
relapse
Gene therapy
product
30-Aug-2017 Still in market Click here for
link to FDA
website
MACI (Vericel
Corporation)
Autologous cultured chondrocytes on a
porcine collagen membrane for the
repair of single or multiple symptom-
atic, full-thickness cartilage defects of
the knee with or without bone involve-
ment in adults
Tissue engi-
neered product
13-Dec-2016 Still in market Click here for
link to FDA
website
Clevecord (HPC,
Cord Blood)
(Cleveland Cord
Blood Center)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
1-Sep-2016 Still in market Click here for
link to FDA
website
HPC, Cord Blood
(Bloodworks)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
28-Jan-2016 Still in market Click here for
link to FDA
website
IMLYGIC (talimo-
gene laherparepvec)
(Amgen Inc.)
Genetically modified oncolytic viral ther-
apy indicated for the local treatment of
unresectable cutaneous, subcutaneous
and nodal lesions in patients with mela-
noma recurrent after initial surgery
Gene therapy
product
27-Oct-2015 Still in market Click here for
link to FDA
website
HPC, Cord Blood
(LifeSouth
For use in unrelated donor hematopoietic
progenitor cell transplantation
Cell therapy
product
13-Jun-2013 Still in market
(continued)
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Table X. (Continued).
Name (MA holder) Product description and indication(s) Product category Date of MA Current status Additional
information
Community Blood
Centers, Inc.)
procedures in conjunction with an
appropriate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Click here for
link to FDA
website
ALLOCORD (SSM
Cardinal Glennon
Children’s Medical
Center)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
30-May-2013 Still in market Click here for
link to FDA
website
Ducord (HPC, Cord
Blood) (Duke Uni-
versity School of
Medicine)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
4-Oct-2012 Still in market Click here for
link to FDA
website
HPC, Cord Blood
(Clinimmune Labs,
University of Colo-
rado Cord Blood
Bank)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
24-May-2012 Still in market Click here for
link to FDA
website
GINTUIT (Organo-
genesis, Inc.)
Allogeneic cultured keratinocytes and
fibroblasts in bovine collagen (cellular
sheets) for topical (non-submerged)
application to a surgically created vas-
cular wound bed in the treatment of
mucogingival conditions in adults
Tissue engi-
neered product
9-Mar-2012 Still in market Click here for
link to FDA
website
Hemacord (HPC,
Cord Blood) (New
York Blood Center,
Inc.)
For use in unrelated donor hematopoietic
progenitor cell transplantation proce-
dures in conjunction with an appropri-
ate preparative regimen for
hematopoietic and immunologic recon-
stitution in patients with disorders
affecting the hematopoietic system that
are inherited, acquired or result from
myeloablative treatment
Cell therapy
product
1-Nov-2011 Still in market Click here for
link to FDA
website
Laviv (Azficel-T)
(Fibrocell Technol-
ogies, Inc.)
Autologous fibroblasts for improvement
of the appearance of moderate-to-
severe nasolabial fold wrinkles in adults
Cell therapy
product
21-Jun-2011 Still in market Click here for
link to FDA
website
PROVENGE (sipu-
leucel-T) (Den-
dreon Corporation)
Autologous cellular immunotherapy indi-
cated for the treatment of asymptomatic
or minimally symptomatic metastatic
castrate-resistant (hormone refractory)
prostate cancer
Cell therapy
product
29-Apr-2010 Still in market Click here for
link to FDA
website
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Figure 1. Number of cell, tissue and gene products with MA per region. *Eight products based on cord blood hematopoietic progenitors for
unrelated donor hematopoietic progenitor cell transplantation have been included in the US’s total number. These hold a MA license only
in the US. Similar products are available in most countries as cell transplants and not as marketed products. The number of products pre-
sented in this figure does not include either products with Regenerative Medicine Advanced Therapy (RMAT) designation (United States
Food and Drug Administration [USFDA]) or products with suspended MA.
Table XI. List of cell/tissue/gene products with RMATDesignation [4] in the United States by USFDA (Sep-2018).
Name (MA holder) Product description and indication
(s)
Product category Date of RMAT
designation
Additional
designations
Additional
information
AT132 (Audentes
Therapeutics, Inc.)
AAV-mediated gene therapy for
the treatment of XLMTM, a
rare monogenic disease caused
by mutations in the MTM1 gene
Gene therapy
product
21-Aug-2018 Rare pediatric
disease; fast
track; orphan
drug
Press release
Romyelocel-L (Cel-
lerant Therapeu-
tics, Inc.)
Off-the-shelf human myeloid pro-
genitor cells for the prevention of
serious bacterial and fungal
infections in patients with de
novo AML undergoing induction
chemotherapy
Cell therapy
product
02-Jul-2018 Press release
VY-AADC (Voyager
Therapeutics, Inc.)
AAV-mediated gene therapy for
the treatment of Parkinson’s dis-
ease in patients with motor fluc-
tuations that are refractory to
medical management
Gene therapy
product
21-Jun-2018 Press release
CLBS14-RfA (Cala-
drius Biosciences,
Inc.)
CD34+ cell therapy program for
the treatment of refractory
angina
Cell therapy
product
19-Jun-2018 Press release
NSR-REP1 (Night-
star Therapeutics
plc)
AAV-mediated gene therapy for
the treatment of choroideremia,
a rare, degenerative, genetic reti-
nal disorder that leads to
blindness
Gene therapy
product
14-Jun-2018 Press release
ABO-102 (Abeona
Therapeutics Inc.)
AAV-mediated gene therapy for
the treatment of Sanfilippo syn-
drome Type A (MPS IIIA), a
rare autosomal-recessive lyso-
somal storage disease
Gene therapy
product
23-Apr-2018 Press release
(continued)
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Table XI. (Continued).
Name (MA holder) Product description and indication
(s)
Product category Date of RMAT
designation
Additional
designations
Additional
information
AmnioFix
(MiMedx)
Allogeneic micronized dehydrated
human amnion/chorion mem-
brane for use in the treatment of
OA of the knee
Tissue engi-
neered product
9-Mar-2018 Press release
CAP-1002 (Capricor
Therapeutics)
Allogeneic cell therapy (cardio-
sphere-derived cells) that is cur-
rently in clinical development for
the treatment of Duchenne mus-
cular dystrophy
Cell therapy
product
5-Feb-2018 Orphan drug;
rare pediatric
disease
Press release
EB-101 (Abeona
Therapeutics Inc.)
Gene-corrected autologous cell
therapy product for patients with
RDEB
Gene therapy
product
29-Jan-2018 Breakthrough
therapy;
orphan drug;
rare pediatric
disease
Press release
MPC therapy (Meso-
blast Limited)
MPC therapy in the treatment of
patients with heart failure with
left ventricular systolic dysfunc-
tion and LVADs
Cell therapy
product
21-Dec-2017 Press release
CEVA101
(Cellvation)
Autologous bone marrowderived
stem cells for the treatment of
traumatic brain injury
Cell therapy
product
8-Nov-2017 Press release
Multistem (Athersys) Proprietary stem cell product for
the treatment of ischemic stroke
Cell therapy
product
5-Oct-2017 Press release
AST-OPC1 (Asterias
Biotherapeutics)
Oligodendrocyte progenitor cells
manufactured from pluripotent
embryonic stem cells for treat-
ment of patients with spinal cord
injury
Cell therapy
product
2-Oct-2017 Press release
LentiGlobin BB305
(Bluebird Bio)
Ex vivomodified autologous
hematopoietic stem cells for
treatment of transfusion-depen-
dent b-thalassemia (also known
as b-thalassemia major) and
severe SCD
Gene therapy
product
1-Oct-2017 Press release
ATIR101TM (Kiadis
Pharma)
Adjunctive immunotherapeutic on
top of allogeneic HSCT
Cell therapy
product
20-Sep-2017 Press release
StrataGraft (Mal-
linckrodt plc)
Autologous skin cell product for
the treatment of deep partial
thickness burns
Tissue engi-
neered product
18-Jul-2017 Press release
Ixmyelocel-T
(Vericel)
Autologous expanded multicellu-
lar (mesenchymal cells, mono-
cytes and alternatively activated
macrophages) product for the
treatment of patients with
advanced heart failure due to
ischemic dilated cardiomyopathy
Cell therapy
product
10-May-2017 Press release
jCell (jCyte) Adult retinal progenitor cells for
the treatment of RP
Cell therapy
product
2-May-2017 Press release
RVT-802 (Enzyvant) Allogeneic thymic tissue for the
treatment of primary immune
deficiency resulting from cDGS
Cell therapy
product
17-Apr-2017 Breakthrough
therapy, rare
pediatric dis-
ease, orphan
drug
Press release
HUMACYL
(Humacyte)
HAV for patients undergoing
hemodialysis
Tissue engi-
neered product
20-Mar-2017 Press release
JCAR017 (Juno
Therapeutics)
Treatment of r/r aggressive large
B-cell non-Hodgkin lymphoma
Cell therapy
product
AAV, adeno-associated virus; XLMTM, X-linked Myotubular Myopathy; AML, acute myeloid leukemia; OA, osteoarthritis; RDEB, reces-
sive dystrophic epidermolysis bullosa; MPC, mesenchymal precursor cell; LVADs, left ventricular assist devices; SCD, sickle cell disease;
HSCT, hematopoietic stem cell transplantation; RP, retinitis pigmentosa; cDGS, complete diGeorge Syndrome; HAV, human acellular
vessel.
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Figure 2. Cell, tissue and gene products with MA worldwide (44 unique products) organized by (A) product type, (B) therapy type and (C)
disease type. “Cell Therapy” products in (B) also include tissue engineered products. Eight products based on cord blood hematopoietic
progenitors for unrelated donor hematopoietic progenitor cell transplantation have been included in the total number. These hold a MA
license only in the US. Similar products are available in most countries as cell transplants and not as marketed products. The number of
products presented in this figure does not include either products with RMAT designation (USFDA) or products with suspended MA.
GVHD, graft-versus-host disease.
Figure 3. Cell, tissue and gene products with MA worldwide (44 unique products) organized by year of MA. Eight products based on cord
blood hematopoietic progenitors for unrelated donor hematopoietic progenitor cell transplantation have been included in the total number
These hold a MA license only in the US. Similar products are available in most countries as cell transplants and not as marketed products
The number of products presented in this figure does not include either products with RMAT designation (USFDA) or products with sus-
pendedMA.
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Sipp (RIKEN, Kobe, Japan) for his help with MA
status of cell, gene and tissue products in East
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